Auspex Secures $25M To Get To NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech garnered a $25 million Series D round, which could be enough to propel it through a Phase III trial and to FDA with its lead candidate. Investors are hoping an approved product could make Auspex an attractive take-out candidate.